Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moran

Showing results (1031-1040 of 1,535) with videos related to

Pageof 154
Sort By:
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Seminars in Reproductive Medicine|September 7, 2018
Integrated Model of Care for Polycystic Ovary SyndromeChau T Tay, Lisa J Moran, Chandrika N Wijeyaratne, et al.
Journal of Neurosurgery. Pediatrics|September 10, 2021
Return of the lesion: a meta-analysis of 1134 angiographically cured pediatric arteriovenous malformationsDavid C Lauzier, Ananth K Vellimana, Arindam R Chatterjee, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|April 1, 1987
Developmental toxicity evaluation of inhaled methyl isobutyl ketone in Fischer 344 rats and CD-1 miceR W Tyl, K A France, L C Fisher, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|March 5, 2018
Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancerM B Bignell, A M Mehta, S Alves, et al.
Pulmonary Pharmacology & Therapeutics|October 9, 2017
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studiesDean Quinn, Christopher N Barnes, Wayne Yates, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|March 21, 2007
Epidemiology of animal exposures presenting to emergency departmentsMark T Steele, O John Ma, Janet Nakase, et al.
Patient Education and Counseling|May 10, 2021
Relationships between self-management strategies and physical activity and diet quality in women with polycystic ovary syndromeStephanie Pirotta, Siew S Lim, Angela Grassi, et al.
Hepatology (Baltimore, Md.)|February 14, 1998
Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infectionM J Moran, A Fontanellas, E Brudieux, et al.
Pageof 154

Showing results (1031-1040 of 1,535) with videos related to

Sort By:
Pageof 154
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Seminars in Reproductive Medicine|September 7, 2018
Integrated Model of Care for Polycystic Ovary SyndromeChau T Tay, Lisa J Moran, Chandrika N Wijeyaratne, et al.
Journal of Neurosurgery. Pediatrics|September 10, 2021
Return of the lesion: a meta-analysis of 1134 angiographically cured pediatric arteriovenous malformationsDavid C Lauzier, Ananth K Vellimana, Arindam R Chatterjee, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|April 1, 1987
Developmental toxicity evaluation of inhaled methyl isobutyl ketone in Fischer 344 rats and CD-1 miceR W Tyl, K A France, L C Fisher, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|March 5, 2018
Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancerM B Bignell, A M Mehta, S Alves, et al.
Pulmonary Pharmacology & Therapeutics|October 9, 2017
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studiesDean Quinn, Christopher N Barnes, Wayne Yates, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|March 21, 2007
Epidemiology of animal exposures presenting to emergency departmentsMark T Steele, O John Ma, Janet Nakase, et al.
Patient Education and Counseling|May 10, 2021
Relationships between self-management strategies and physical activity and diet quality in women with polycystic ovary syndromeStephanie Pirotta, Siew S Lim, Angela Grassi, et al.
Hepatology (Baltimore, Md.)|February 14, 1998
Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infectionM J Moran, A Fontanellas, E Brudieux, et al.
Pageof 154